Patents by Inventor Brendan Kelly

Brendan Kelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12275739
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Grant
    Filed: November 6, 2023
    Date of Patent: April 15, 2025
    Assignee: BIOMEA FUSION, INC.
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Publication number: 20250060318
    Abstract: Embodiments pertain to methods of evaluating fiber quality by (1) receiving at least one in-line hologram image of the fiber; (2) reconstructing the in-line hologram image of the fiber into at least one three-dimensional image of the fiber that includes fiber-related data; and (3) correlating the fiber-related data to fiber quality. Such methods may also include: (4) adjusting fiber-related conditions; and (5) repeating steps 1-3 after the adjustment. Further embodiments pertain to systems for evaluating fiber quality in accordance with the aforementioned methods. Such systems may include a receiving area with a region for housing a fiber, a light source associated with the receiving area, a chamber associated with the light source and receiving area, a camera within the chamber, a processor in electrical communication with the camera, a storage device, an algorithm associated with the storage device and a graphical user interface (GUI) associated with the processor.
    Type: Application
    Filed: December 23, 2022
    Publication date: February 20, 2025
    Applicants: Texas Tech University System, University of Toledo
    Inventors: Aniruddha Ray, Brendan Kelly, Hamed Sari-Sarraf
  • Patent number: 12116371
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Grant
    Filed: July 31, 2023
    Date of Patent: October 15, 2024
    Assignee: BIOMEA FUSION, INC.
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Patent number: 12077544
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Grant
    Filed: January 9, 2023
    Date of Patent: September 3, 2024
    Assignee: Biomea Fusion, Inc.
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Patent number: 12039639
    Abstract: Systems and methods reconstruct an image of a subject or object by performing an iterative reconstruction method to produce a plurality of intermediate images and the image of the subject, and transforming at least one selected intermediate image from the plurality of intermediate images using a quasi-projection operator. The quasi-projection operator includes a deep-learning model configured to map the at least one selected intermediate image to at least one regularized intermediate image. In addition, systems and methods for training the deep-learning model using a training data set that includes a plurality of training images and a plurality of corresponding training object images is disclosed.
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: July 16, 2024
    Assignee: Washington University
    Inventors: Mark Anastasio, Thomas Matthews, Brendan Kelly
  • Patent number: 11912977
    Abstract: A stem cell production system provided with a preintroduction cell-feeding solution channel 20 through which a solution containing cells passes, an induction factor-feeding solution mechanism 21 for feeding a pluripotency induction factor to the preintroduction cell-feeding solution channel 20, a factor introduction device 30 connected to the preintroduction cell-feeding solution channel 20 for making cells with induction factor introduced by introducing the pluripotency induction factor into the cells, a cell mass-making device 40 for making multiple cell masses comprising stem cells by culturing the cells with induction factor introduced, and a packaging device 100 for sequentially packaging each of the multiple cell masses.
    Type: Grant
    Filed: August 3, 2022
    Date of Patent: February 27, 2024
    Assignee: I Peace, Inc.
    Inventors: Koji Tanabe, Brendan Kelly, Kenta Suto, Hidenori Shimoda, Ryoji Hiraide
  • Patent number: 11845753
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: December 19, 2023
    Assignee: Biomea Fusion, Inc.
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Patent number: 11702421
    Abstract: Disclosed herein are heterocyclic compounds according to formula (I) having the structure that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-HLL interaction. Also disclosed are pharmaceutical compositions that include compounds according to formula (I). Methods of using the menin-HLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: July 18, 2023
    Assignee: BIOMEA FUSION, LLC
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Publication number: 20230122062
    Abstract: The present disclosure provides a system, apparatus and method for generating randomly aligned fiber beards for evaluation. The system comprises abase and an x-axis frame member couples to and is positioned parallel to the base. A y-axis frame member is couple to and positioned perpendicular to the base. A sample plate is removably coupled to the y-axis frame member and defines one or more holes. A fiber clamp couples to and is movable by the x-axis frame member perpendicularly to the sample plate.
    Type: Application
    Filed: October 21, 2022
    Publication date: April 20, 2023
    Applicant: TEXAS TECH UNIVERSITY SYSTEM
    Inventor: Brendan Kelly
  • Patent number: 11579137
    Abstract: Disclosed is a system and method for extraction of information of within sample distribution of fiber quality from high-volume instrument (HVI) fibrogram to better predict yarn quality than the standard HVI output. The present invention allows for information on fiber quality to be obtained while avoiding testing samples with more expensive techniques. The disclosed system and method extracts HVI data for collecting a respective set of initial fibrograms from a set of fiber samples and representing them as a distance matrix to form a matrix of transformed fibrogram data, said matrix of transformed fibrogram data comprising a vector of scores to represent each sample and thereafter explaining variation in yarn quality by extracting all of the information available from the fibrogram.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: February 14, 2023
    Assignee: Texas Tech University System
    Inventors: Brendan Kelly, Eric Hequet, Md Abu Sayeed, Zach Hinds
  • Patent number: 11538485
    Abstract: A method watermarks speech data by using a generator to generate speech data including a watermark. The generator is trained to generate the speech data including the watermark. The training process generates first speech from the generator. The first speech data is configured to represent speech. The first speech data includes a candidate watermark. The training also produces an inconsistency message as a function of at least one difference between the first speech data and at least authentic speech data. The training further includes transforming the first speech data, including the candidate watermark, using a watermark robustness module to produce transformed speech data including a transformed candidate watermark. The transformed speech data includes a transformed candidate watermark. The training further produces a watermark-detectability message, using a watermark detection machine learning system, relating to one or more desirable watermark features of the transformed candidate watermark.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: December 27, 2022
    Assignee: Modulate, Inc.
    Inventors: William Carter Huffman, Brendan Kelly
  • Patent number: 11518974
    Abstract: A stem cell production system provided with a preintroduction cell-feeding solution channel 20 through which a solution containing cells passes, an induction factor-feeding solution mechanism 21 for feeding a pluripotency induction factor to the preintroduction cell-feeding solution channel 20, a factor introduction device 30 connected to the preintroduction cell-feeding solution channel 20 for making cells with induction factor introduced by introducing the pluripotency induction factor into the cells, a cell mass-making device 40 for making multiple cell masses comprising stem cells by culturing the cells with induction factor introduced, and a packaging device 100 for sequentially packaging each of the multiple cell masses.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: December 6, 2022
    Assignee: I PEACE, INC.
    Inventors: Koji Tanabe, Brendan Kelly, Kenta Suto, Hidenori Shimoda, Ryoji Hiraide
  • Patent number: 11403792
    Abstract: Systems and methods for reconstructing an image of a subject or object based on a plurality of measured signals representing the subject or object obtained by an imaging device are disclosed. The systems and methods reconstruct the image of the subject or object by performing an iterative reconstruction method to produce a plurality of intermediate images and the image of the subject, and transforming at least one selected intermediate image from the plurality of intermediate images using a quasi-projection operator. The quasi-projection operator includes a deep-learning model configured to map the at least one selected intermediate image to at least one regularized intermediate image. In addition, systems and methods for training the deep-learning model using a training data set that includes a plurality of training images and a plurality of corresponding training object images is disclosed.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: August 2, 2022
    Assignee: Washington University
    Inventors: Mark Anastasio, Thomas Matthews, Brendan Kelly
  • Publication number: 20220169627
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Application
    Filed: June 18, 2021
    Publication date: June 2, 2022
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Patent number: 11286454
    Abstract: The present invention provides a stem cell manufacturing system comprising: a sending channel (20) through which a solution containing cells flows; an apparatus (30) which is connected to the sending channel (20) and transfers a pluripotency inducer into the cells to produce cells harboring the inducer; and an apparatus (40) which cultures the cells harboring the inducer to produce cell clusters consisting of stem cells.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: March 29, 2022
    Assignee: I PEACE, INC.
    Inventors: Koji Tanabe, Brendan Kelly, Kenta Suto
  • Publication number: 20220024936
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 27, 2022
    Inventors: Thomas BUTLER, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Patent number: 11174263
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: November 16, 2021
    Assignee: BIOMEA FUSION, INC.
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Patent number: 11084825
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL inter-action; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: August 10, 2021
    Assignee: BIOMEA FUSION, LLC
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Publication number: 20210050025
    Abstract: A method watermarks speech data by using a generator to generate speech data including a watermark. The generator is trained to generate the speech data including the watermark. The training process generates first speech from the generator. The first speech data is configured to represent speech. The first speech data includes a candidate watermark. The training also produces an inconsistency message as a function of at least one difference between the first speech data and at least authentic speech data. The training further includes transforming the first speech data, including the candidate watermark, using a watermark robustness module to produce transformed speech data including a transformed candidate watermark. The transformed speech data includes a transformed candidate watermark. The training further produces a watermark-detectability message, using a watermark detection machine learning system, relating to one or more desirable watermark features of the transformed candidate watermark.
    Type: Application
    Filed: August 14, 2020
    Publication date: February 18, 2021
    Inventors: William Carter Huffman, Brendan Kelly
  • Publication number: 20200363391
    Abstract: Disclosed is a system and method for extraction of information of within sample distribution of fiber quality from high-volume instrument (HVI) fibrogram to better predict yarn quality than the standard HVI output. The present invention allows for information on fiber quality to be obtained while avoiding testing samples with more expensive techniques. The disclosed system and method extracts HVI data for collecting a respective set of initial fibrograms from a set of fiber samples and representing them as a distance matrix to form a matrix of transformed fibrogram data, said matrix of transformed fibrogram data comprising a vector of scores to represent each sample and thereafter explaining variation in yarn quality by extracting all of the information available from the fibrogram.
    Type: Application
    Filed: November 13, 2018
    Publication date: November 19, 2020
    Applicant: TEXAS TECH UNIVERSITY SYSTEM
    Inventors: Brendan Kelly, Eric Hequet, Md Abu Sayeed, Zach Hinds